Exhibit 99.1 RAP-219 Lead Program Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update BOSTON, Mass. and SAN DIEGO, Calif. – May 8, 2025 – Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the first quarter ending March 31, 2025, and provided a business update. "2025 re ...